Summary
75.64 -2.10(-2.70%)11/04/2024
WGS (WGS)
WGS (WGS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.70 | 1.68 | -16.93 | -38.58 | 942.20 | 0.00 | 0.00 | 0.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 75.64 | |
| Open | 77.70 | |
| High | 79.62 | |
| Low | 74.16 | |
| Volume | 270,047 | |
| Change | -2.10 | |
| Change % | -2.70 | |
| Avg Volume (20 Days) | 60,144 | |
| Volume/Avg Volume (20 Days) Ratio | 4.49 | |
| 52 Week Range | 0.00 - 0.00 | |
| Price vs 52 Week High | inf% | |
| Price vs 52 Week Low | inf% | |
| Range | 0.00 | |
| Gap Up/Down | -0.18 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,094 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 0.00 | |
| Book Value | 0.0000 | |
| Earnings Per Share | 0.0000 | |
| EPS Estimate Current Quarter | 0.0000 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | 0.0000 | |
| EPS Estimate Next Year | 0.0000 | |
| Diluted EPS (TTM) | 0.0000 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 0 | |
| Shares Float | 0 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 0.00 | |
11/04 11:01 EST - zacks.com
Best Momentum Stocks to Buy for November 4th
WGS, CVNA and NBBK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 4, 2024.
Best Momentum Stocks to Buy for November 4th
WGS, CVNA and NBBK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 4, 2024.
11/04 06:46 EST - zacks.com
New Strong Buy Stocks for November 4th
CFFN, VLRS, NBBK, WGS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on November 4, 2024.
New Strong Buy Stocks for November 4th
CFFN, VLRS, NBBK, WGS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on November 4, 2024.
10/31 18:11 EST - seekingalpha.com
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Holdings Corp. have outperformed the market and beaten analysts expectations. Natera's oncology tests driving revenue growth and GeneDx focusing on newborn rare disease diagnostics. Both firms have been improving financial metrics, with Natera showing strong revenue growth driven by oncology tests in Q2 2024, while GeneDx achieved profitability in Q3 2024.
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Holdings Corp. have outperformed the market and beaten analysts expectations. Natera's oncology tests driving revenue growth and GeneDx focusing on newborn rare disease diagnostics. Both firms have been improving financial metrics, with Natera showing strong revenue growth driven by oncology tests in Q2 2024, while GeneDx achieved profitability in Q3 2024.
10/30 15:10 EST - seekingalpha.com
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of genetic conditions. The company's Q3 earnings led to a >50% uplift in the share price this week, with ~$287 revenues pledged for 2024, and a gross margin of >60%.
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of genetic conditions. The company's Q3 earnings led to a >50% uplift in the share price this week, with ~$287 revenues pledged for 2024, and a gross margin of >60%.
10/29 18:46 EST - seekingalpha.com
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen William Bonello - Craig Hallum Capital Group Mark Massaro - BTIG Matthew Sykes - Goldman Sachs Group, Inc. Brandon Couillard - Wells Fargo Securities Matthew Stanton - Jefferies Operator Thank you for standing by, and welcome to the GeneDx Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode and after the speaker's presentation we will have a question-and-answer session Keep in mind that this call is being recorded.
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen William Bonello - Craig Hallum Capital Group Mark Massaro - BTIG Matthew Sykes - Goldman Sachs Group, Inc. Brandon Couillard - Wells Fargo Securities Matthew Stanton - Jefferies Operator Thank you for standing by, and welcome to the GeneDx Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode and after the speaker's presentation we will have a question-and-answer session Keep in mind that this call is being recorded.
10/29 11:11 EST - benzinga.com
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx Holdings WGS stock is trading higher on Tuesday.
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
GeneDx Holdings WGS stock is trading higher on Tuesday.
10/29 10:10 EST - zacks.com
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago.
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago.
10/29 08:00 EST - businesswire.com
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2024.
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2024.
10/24 11:10 EST - businesswire.com
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Association, published peer-reviewed research from the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, the largest study of its kind to explore the utility of whole genome sequencing (WGS) to identify 255 early onset genetic conditions in newborns from a diverse populatio.
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Association, published peer-reviewed research from the GUARDIAN (Genomic Uniform-screening Against Rare Diseases In All Newborns) study, the largest study of its kind to explore the utility of whole genome sequencing (WGS) to identify 255 early onset genetic conditions in newborns from a diverse populatio.
10/21 10:00 EST - seekingalpha.com
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarter performance exceeded expectations, driven by over 125% year-over-year growth in its whole exome and genome business, now 74% of total revenue. GeneDx reduced its quarterly cash burn significantly and anticipates profitability by 2025, with increasing reimbursement rates and expanding Medicaid coverage boosting revenue.
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarter performance exceeded expectations, driven by over 125% year-over-year growth in its whole exome and genome business, now 74% of total revenue. GeneDx reduced its quarterly cash burn significantly and anticipates profitability by 2025, with increasing reimbursement rates and expanding Medicaid coverage boosting revenue.
10/08 08:30 EST - businesswire.com
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to expand standard newborn screening (NBS). Through these studies, GeneDx has conducted more gNBS than any other lab and.
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for more than 14,000 infants through its participation in groundbreaking research studies which aim to explore the clinical utility and implementation of utilizing genome sequencing to expand standard newborn screening (NBS). Through these studies, GeneDx has conducted more gNBS than any other lab and.
10/03 16:05 EST - businesswire.com
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024.
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024.
09/27 16:05 EST - businesswire.com
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the compensation committee of GeneDx's board of directors granted restricted stock units (“RSUs”).
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the compensation committee of GeneDx's board of directors granted restricted stock units (“RSUs”).
09/19 08:00 EST - investors.com
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.
08/05 11:16 EST - zacks.com
Best Momentum Stocks to Buy for August 5th
WGS, MCY and MHO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2024.
Best Momentum Stocks to Buy for August 5th
WGS, MCY and MHO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 5, 2024.
08/05 11:01 EST - zacks.com
How Much Upside is Left in GENEDX HOLDINGS (WGS)? Wall Street Analysts Think 40.34%
The consensus price target hints at a 40.3% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in GENEDX HOLDINGS (WGS)? Wall Street Analysts Think 40.34%
The consensus price target hints at a 40.3% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
08/05 07:05 EST - zacks.com
New Strong Buy Stocks for August 5th
KGC, MCY, WGS, CHRW and FULC have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2023.
New Strong Buy Stocks for August 5th
KGC, MCY, WGS, CHRW and FULC have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2023.
07/30 21:02 EST - seekingalpha.com
GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies William Bonello - Craig Hallum Mark Massaro - BTIG Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the GeneDx Second Quarter 2024 Earnings Conference Call.
GeneDx Holdings Corp. (WGS) Q2 2024 Earnings Call Transcript
GeneDx Holdings Corp. (NASDAQ:WGS ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Sabrina Dunbar - Commercial Chief of Staff Katherine Stueland - President and Chief Executive Officer Kevin Feeley - Chief Financial Officer Conference Call Participants Tycho Peterson - Jefferies William Bonello - Craig Hallum Mark Massaro - BTIG Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the GeneDx Second Quarter 2024 Earnings Conference Call.
07/30 18:46 EST - zacks.com
GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $1.65 per share a year ago.
GeneDx Holdings Corp. (WGS) Reports Q2 Loss, Tops Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $1.65 per share a year ago.
07/30 16:05 EST - businesswire.com
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the second quarter of 2024.
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the second quarter of 2024.